Navigation Links
Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20
Date:5/10/2011

SAN FRANCISCO, May 10, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Helix BioPharma Corporation (AMEX: HBP, TSX: HBP) ("the Company") with a twelve month target price of $6.20. Ross Silver, Principal Analyst at Vista Partners stated, "The Company is developing products for the treatment and prevention of cancer. The first and most advanced, Interferon alpha-2b, is a potent immuno-modulatory drug compound that has been formulated as a topical cream ("TIFNα2b") using Helix's unique, patented Biphasix™ platform technology which is intended to resolve low-grade cervical intraepithelial neoplasia grade 1 or 2 ("CIN 1 or 2") lesions. We believe TIFNα2b, if approved, could have revenues in excess of $500M globally, given the fact that the prospective market size is considerable, with approximately 1.3 million new cases of low-grade cervical lesions diagnosed annually each year in the U.S. alone today for which there are no approved pharmaceutical therapies." Mr. Silver concludes, "The Company's L-DOS47 is the first targeted therapeutic immunoconjugate under development based upon Helix's DOS47 technology. Helix's L-DOS47 is a new drug in development that is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer ("NSCLC")."

To download a FREE copy of the Helix BioPharma Corporation research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. Vista Partners LLC is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:
877.215.4813 or info@vistapglobal.com


'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
3. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
7. NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
8. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
9. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... for the fourth quarter and year ended December 31, ... of transformational progress for Orexigen, beginning with the re-acquisition ... Commencing early March, the team at Orexigen demonstrated remarkable ... which reshaped and strengthened our Company while rewarding us ...
(Date:3/28/2017)... and TORONTO , March ... leading full service medical device development firm, ... the visionary Toronto -based medical device ... will better serve medtech companies throughout North ... resources and experienced medical device talent spanning the design, ...
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is ... to take the Diabetes Risk Test to find out if they are at risk ... Airports will light up the evening sky by programming the LAX pylons the color ...
(Date:3/28/2017)... YORK (PRWEB) , ... March 28, 2017 , ... ... NTX Technology™, is the first technology to directly address the resolution to globally ... NTX Technology™ is a patented compound of FDA and TTB approved ingredients that ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, ... be invited to the Siemens Healthineers annual customer education symposium, a world-class learning ... take place from March 27 - 31, 2017 at the Atlanta Marriott Marquis ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret is ... Pharm.D., FASCP. The program was recently launched on March 1, and Dr. Wentz ... function. , Dr. Izabella Wentz is a licensed pharmacist and a foremost ...
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have soared 82% ... Trends Report). As travelers visit both urban destinations, they are faced with exploration ... exposure. In response, the outdoor industry has blurred the lines between fashion and ...
Breaking Medicine News(10 mins):